collection
https://read.qxmd.com/read/26245731/low-alt-levels-independently-associated-with-22-year-all-cause-mortality-among-coronary-heart-disease-patients
#21
JOURNAL ARTICLE
N Peltz-Sinvani, R Klempfner, E Ramaty, B A Sela, I Goldenberg, G Segal
BACKGROUND: Low alanine aminotransferase (ALT) blood levels are known to be associated with frailty and increased risk of long-term mortality in certain populations. However, the contribution of this marker to long-term outcome has not been assessed in patients with chronic coronary heart disease. OBJECTIVE: The aim of the current study was to assess the association between low ALT values and long-term, 22.8-year, all-cause mortality in this population. PARTICIPANTS: We examined the association of low ALT (<17 IU/l) with long-term all-cause mortality in the Bezafibrate Infarction Prevention (BIP) Registry population...
February 2016: Journal of General Internal Medicine
https://read.qxmd.com/read/27016105/long-term-effectiveness-and-safety-of-pravastatin-in-patients-with-coronary-heart-disease-sixteen-years-of-follow-up-of-the-lipid-study
#22
REVIEW
Wendy E Hague, John Simes, Adrienne Kirby, Anthony C Keech, Harvey D White, David Hunt, Paul J Nestel, David M Colquhoun, Helen Pater, Ralph A Stewart, David R Sullivan, Peter L Thompson, Malcolm West, Paul P Glasziou, Andrew M Tonkin
BACKGROUND: We aimed to assess the long-term effects of treatment with statin therapy on all-cause mortality, cause-specific mortality, and cancer incidence from extended follow-up of the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) trial. METHODS AND RESULTS: LIPID initially compared pravastatin and placebo over 6 years in 9014 patients with previous coronary heart disease. After the double-blind period, all patients were offered open-label statin therapy...
May 10, 2016: Circulation
https://read.qxmd.com/read/26881813/discriminative-power-of-the-heart-score-for-obstructive-coronary-artery-disease-in-acute-chest-pain-patients-referred-for-ccta
#23
JOURNAL ARTICLE
Adriana Q Kolff, Michiel J Bom, Remco J J Knol, Friso M van de Zant, Petrus M van der Zee, Jan H Cornel
OBJECTIVE: To investigate the ability of the HEART score to predict the presence of obstructive coronary artery disease (CAD) determined by coronary computed tomography angiography (CCTA) and its ability to predict the occurrence of major adverse cardiac events (MACE) in patients referred for CCTA after emergency department (ED) presentation. METHODS: From December 2011 to August 2014, 710 ED patients with chest pain who underwent CCTA within 30 days were included...
March 2016: Critical Pathways in Cardiology
https://read.qxmd.com/read/26906397/the-addition-of-depression-to-the-framingham-risk-equation-model-for-predicting-coronary-heart-disease-risk-in-women
#24
JOURNAL ARTICLE
Adrienne O'Neil, Aaron J Fisher, Katherine J Kibbey, Felice N Jacka, Mark A Kotowicz, Lana J Williams, Amanda L Stuart, Michael Berk, Paul A Lewandowski, John J Atherton, Craig B Taylor, Julie A Pasco
BACKGROUND: Depression is widely considered to be an independent and robust predictor of Coronary Heart Disease (CHD), however is seldom considered in the context of formal risk assessment. We assessed whether the addition of depression to the Framingham Risk Equation (FRE) improved accuracy for predicting 10-year CHD in a sample of women. DESIGN: A prospective, longitudinal design comprising an age-stratified, population-based sample of Australian women collected between 1993 and 2011 (n=862)...
June 2016: Preventive Medicine
https://read.qxmd.com/read/27012910/how-does-sprint-systolic-blood-pressure-intervention-trial-direct-hypertension-treatment-targets-for-ckd
#25
EDITORIAL
Sandra J Taler
No abstract text is available yet for this article.
July 2016: American Journal of Kidney Diseases
https://read.qxmd.com/read/25838421/high-density-lipoprotein-hdl-phospholipid-content-and-cholesterol-efflux-capacity-are-reduced-in-patients-with-very-high-hdl-cholesterol-and-coronary-disease
#26
JOURNAL ARTICLE
Anandita P Agarwala, Amrith Rodrigues, Marjorie Risman, Mary McCoy, Kevin Trindade, Liming Qu, Marina Cuchel, Jeffrey Billheimer, Daniel J Rader
OBJECTIVE: Plasma levels of high-density lipoprotein cholesterol (HDL-C) are strongly inversely associated with coronary artery disease (CAD), and high HDL-C is generally associated with reduced risk of CAD. Extremely high HDL-C with CAD is an unusual phenotype, and we hypothesized that the HDL in such individuals may have an altered composition and reduced function when compared with controls with similarly high HDL-C and no CAD. APPROACH AND RESULTS: Fifty-five subjects with very high HDL-C (mean, 86 mg/dL) and onset of CAD at the age of ≈ 60 years with no known risk factors for CAD (cases) were identified through systematic recruitment...
June 2015: Arteriosclerosis, Thrombosis, and Vascular Biology
https://read.qxmd.com/read/25634834/cholesterol-overloaded-hdl-particles-are-independently-associated-with-progression-of-carotid-atherosclerosis-in-a-cardiovascular-disease-free-population-a-community-based-cohort-study
#27
JOURNAL ARTICLE
Yue Qi, Jie Fan, Jing Liu, Wei Wang, Miao Wang, Jiayi Sun, Jun Liu, Wuxiang Xie, Fan Zhao, Yan Li, Dong Zhao
BACKGROUND: Cholesterol-overloaded high-density lipoprotein (HDL) particles exert a negative impact on the antiatherogenic function of HDL in experimental studies. However, it remains unclear whether cholesterol-overloaded HDL particle is involved in the development of atherosclerosis in humans. OBJECTIVES: The objective of this study was to explore whether cholesterol-overloaded HDL particles are associated with the progression of carotid atherosclerosis in a cardiovascular disease-free population...
February 3, 2015: Journal of the American College of Cardiology
https://read.qxmd.com/read/26951318/cardiovascular-disease-risk-profiles-in-survivors-of-adolescent-and-young-adult-aya-cancer-the-kaiser-permanente-aya-cancer-survivors-study
#28
JOURNAL ARTICLE
Chun Chao, Lanfang Xu, Smita Bhatia, Robert Cooper, Somjot Brar, F Lennie Wong, Saro H Armenian
PURPOSE: To describe the epidemiology and risk factors for cardiovascular disease (CVD) in survivors of adolescent and young adult (AYA) cancer. METHODS: We identified a retrospective cohort of 2-year survivors of AYA cancer who were diagnosed between the ages of 15 to 39 years (1998 to 2009) at Kaiser Permanente Southern California. A comparison group without cancer was selected and matched 10:1 to cancer survivors on the basis of age, sex, Kaiser Permanente Southern California membership, and calendar year...
May 10, 2016: Journal of Clinical Oncology
https://read.qxmd.com/read/26687339/effects-of-combination-of-ezetimibe-and-rosuvastatin-on-coronary-artery-plaque-in-patients-with-coronary-heart-disease
#29
RANDOMIZED CONTROLLED TRIAL
Xiaofang Wang, Xiaoyan Zhao, Ling Li, Haimu Yao, Yan Jiang, Jinying Zhang
BACKGROUND: In approximately 80% of cardiovascular disease-related deaths, patients suffer from coronary atherosclerotic heart disease. Ezetimibe is the first intestinal cholesterol absorption inhibitor. Its combination with statins for treating coronary atherosclerotic heart disease has attracted attention worldwide. METHODS: The study group comprised 106 patients with coronary atherosclerotic heart disease and hyperlipidaemia. Each was randomly assigned to one of two groups: (1) Ezetimibe (10mg, once a night) plus rosuvastatin (10mg, once a night) (n=55) or (2) Rosuvastatin alone (10mg, once a night) (n=51)...
May 2016: Heart, Lung & Circulation
https://read.qxmd.com/read/26746178/dietary-and-policy-priorities-for-cardiovascular-disease-diabetes-and-obesity-a-comprehensive-review
#30
REVIEW
Dariush Mozaffarian
Suboptimal nutrition is a leading cause of poor health. Nutrition and policy science have advanced rapidly, creating confusion yet also providing powerful opportunities to reduce the adverse health and economic impacts of poor diets. This review considers the history, new evidence, controversies, and corresponding lessons for modern dietary and policy priorities for cardiovascular diseases, obesity, and diabetes mellitus. Major identified themes include the importance of evaluating the full diversity of diet-related risk pathways, not only blood lipids or obesity; focusing on foods and overall diet patterns, rather than single isolated nutrients; recognizing the complex influences of different foods on long-term weight regulation, rather than simply counting calories; and characterizing and implementing evidence-based strategies, including policy approaches, for lifestyle change...
January 12, 2016: Circulation
https://read.qxmd.com/read/25468918/dyslipidaemia-what-s-around-the-corner
#31
JOURNAL ARTICLE
Anthony S Wierzbicki, Dilinika Perera, Mfon Ewang-Emukowhate
Hyperlipidaemia is a major risk factor for the development of atherosclerosis and cardiovascular disease. Statins are the mainstay of therapy and new guidelines focus on the use of these agents without specific targets for low-density lipoprotein (LDL)-cholesterol or non high-density lipoprotein (HDL)-cholesterol. However, patients remain at risk of cardiovascular disease despite statin therapy so new drugs are required. This article reviews therapies in development to further lower LDL-cholesterol (Proprotein convertase subtilisin/kexin-9 (PCSK-9) inhibitors), raise HDL-holesterol (cholesterol ester transfer protein inhibitors (CETPIs)) and reduce triglycerides (novel peroxisome proliferator-activated receptor (PPAR)-agonists and omega-3 fatty acid preparations)...
December 2014: Clinical Medicine: Journal of the Royal College of Physicians of London
https://read.qxmd.com/read/23735860/when-should-we-measure-lipoprotein-a
#32
REVIEW
Karam M Kostner, Winfried März, Gerhard M Kostner
Recently published epidemiological and genetic studies strongly suggest a causal relationship of elevated concentrations of lipoprotein (a) [Lp(a)] with cardiovascular disease (CVD), independent of low-density lipoproteins (LDLs), reduced high density lipoproteins (HDL), and other traditional CVD risk factors. The atherogenicity of Lp(a) at a molecular and cellular level is caused by interference with the fibrinolytic system, the affinity to secretory phospholipase A2, the interaction with extracellular matrix glycoproteins, and the binding to scavenger receptors on macrophages...
November 2013: European Heart Journal
https://read.qxmd.com/read/26492546/emerging-innovative-therapeutic-approaches-targeting-pcsk9-to-lower-lipids
#33
REVIEW
G P S Shantha, J G Robinson
Statins are established therapies for cardiovascular disease prevention and ezetimibe has recently been shown to modestly reduce cardiovascular events when added to background statin therapy. Yet here remains a clear unmet need for additional therapies aimed at lowering low density lipoprotein cholesterol (LDL-C) to further reduce cardiovascular risk. Multiple strategies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition have emerged as effective modalities for LDL-C lowering. PCSK9 monoclonal antibodies are the farthest along in clinical development and alirocumab and evolocumab were approved for clinical use by regulatory agencies in 2015...
January 2016: Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/26547456/predicting-the-overuse-of-pcsk-9-inhibitors
#34
JOURNAL ARTICLE
Rene Rodriguez-Gutierrez, Nilay D Shah, Victor M Montori
No abstract text is available yet for this article.
November 10, 2015: JAMA
https://read.qxmd.com/read/26545013/atherosclerosis-stabilization-with-pcsk-9-inhibition-an-evolving-concept-for-cardiovascular-prevention
#35
JOURNAL ARTICLE
Jennifer G Robinson, Donald D Heistad, Keith A A Fox
Monoclonal antibodies (mAbs) to proprotein convertase subtilisin/kexin type 9 (PCSK-9) can further lower LDL-C by ≥60% in statin-treated patients. Preliminary data suggest they may reduce cardiovascular (CVD) events. Ongoing PCSK-9 mAb cardiovascular outcomes trials could provide the opportunity to determine whether a "legacy effect" similar to that observed for statins will occur over the post-trial observation period. We hypothesize these trials could demonstrate that (1) very aggressive LDL-C lowering with PCSK-9 mAbs added to background statin therapy will induce extensive atherosclerosis stabilization and regression in the large majority of treated patients, and (2) continued maintenance therapy with high intensity statin therapy (with or without ezetimibe) should then inhibit new plaque formation, with a long-term prevention of CVD events...
December 2015: Atherosclerosis
https://read.qxmd.com/read/26702085/population-trends-in-aspirin-use-for-cardiovascular-disease-prevention-1980-2009-the-minnesota-heart-survey
#36
JOURNAL ARTICLE
Russell V Luepker, Lyn M Steffen, Sue Duval, Nicole D Zantek, Xia Zhou, Alan T Hirsch
BACKGROUND: Daily low-dose aspirin is recommended for primary prevention of myocardial infarction and stroke in higher-risk patients. Population trends in aspirin use for cardiovascular disease (CVD) prevention in an urban population (Minneapolis/St. Paul, 2010 population 2.85 million) from 1980 to 2009 were evaluated. METHODS AND RESULTS: Surveys of randomly selected adults aged 25 to 74 years were collected at 5-year intervals. Self-reports of regular aspirin use for CVD prevention and history of CVD were obtained...
December 23, 2015: Journal of the American Heart Association
https://read.qxmd.com/read/26724178/blood-pressure-lowering-for-prevention-of-cardiovascular-disease-and-death-a-systematic-review-and-meta-analysis
#37
REVIEW
Dena Ettehad, Connor A Emdin, Amit Kiran, Simon G Anderson, Thomas Callender, Jonathan Emberson, John Chalmers, Anthony Rodgers, Kazem Rahimi
BACKGROUND: The benefits of blood pressure lowering treatment for prevention of cardiovascular disease are well established. However, the extent to which these effects differ by baseline blood pressure, presence of comorbidities, or drug class is less clear. We therefore performed a systematic review and meta-analysis to clarify these differences. METHOD: For this systematic review and meta-analysis, we searched MEDLINE for large-scale blood pressure lowering trials, published between Jan 1, 1966, and July 7, 2015, and we searched the medical literature to identify trials up to Nov 9, 2015...
March 5, 2016: Lancet
https://read.qxmd.com/read/26497967/benefits-and-risks-of-antihypertensive-medications-in-the-elderly
#38
REVIEW
D A Butt, P J Harvey
Hypertension is highly prevalent in older age and accounts for a large proportion of cardiovascular (CV) morbidity and mortality worldwide. Isolated systolic hypertension is more common in the elderly than younger adults and associated with poor outcomes such as cerebrovascular disease and acute coronary events. International guidelines are inconsistent in providing recommendations on optimal blood pressure targets in hypertensive elderly patients as a result of the limited evidence in this population. Evidence from clinical trials supports the use of antihypertensive drugs in hypertensive elderly patients due to benefits in reducing CV disease and mortality...
December 2015: Journal of Internal Medicine
https://read.qxmd.com/read/24641225/pharmacological-management-of-hypertension-in-the-elderly-certitudes-and-controversies
#39
REVIEW
Karolina Piotrowicz, Ewa Kucharska, Anna Skalska, Aleksander Kwater, Seetha Bhagavatula, Jerzy Gasowski
This paper summarizes the evidence supporting the pharmacological treatment of hypertension in the elderly as well as some the remaining controversies. The world is becoming progressively older and with that, the prevalence of hypertension is increasing. A peculiar form of hypertension, most prevalent among the elderly, is isolated systolic hypertension (ISH). Hypertension in the elderly, especially when systolic blood pressure (SBP) exceeds 160 mm Hg should be treated. Lowering the SBP to less than 150 mm Hg confers substantial cardiovascular protection...
2014: Current Pharmaceutical Design
https://read.qxmd.com/read/26572796/association-of-coffee-consumption-with-total-and-cause-specific-mortality-in-3-large-prospective-cohorts
#40
JOURNAL ARTICLE
Ming Ding, Ambika Satija, Shilpa N Bhupathiraju, Yang Hu, Qi Sun, Jiali Han, Esther Lopez-Garcia, Walter Willett, Rob M van Dam, Frank B Hu
BACKGROUND: The association between consumption of caffeinated and decaffeinated coffee and risk of mortality remains inconclusive. METHODS AND RESULTS: We examined the associations of consumption of total, caffeinated, and decaffeinated coffee with risk of subsequent total and cause-specific mortality among 74,890 women in the Nurses' Health Study (NHS), 93,054 women in the Nurses' Health Study II, and 40,557 men in the Health Professionals Follow-up Study. Coffee consumption was assessed at baseline using a semiquantitative food frequency questionnaire...
December 15, 2015: Circulation
label_collection
label_collection
2764
2
3
2015-12-05 15:40:35
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.